This is one of Roadmap's ready-made topic templates — a starting point for tracking something over time without writing a tracking brief from scratch.
Roadmap is an AI-assisted document editor: markdown with a live preview, a discussion panel where you can ask the AI about a specific section and apply its suggested edit straight to the text (you choose exactly what goes into each request's context), version history with restore, and export in multiple formats. Its "AI Update" button, on any document, searches the web for what has changed since you last checked and updates the document — with dates and sources — only when it finds something genuinely new.
To use this template: click "Open in Editor" above to copy it into your own documents, then press "AI Update" whenever you want to check for news. Browse the sidebar for more topics and categories.
Disease Research: Type 2 Diabetes
Brief
Tracking scientific publications and clinical trials on type 2 diabetes: completed studies, new drug approvals from regulators (FDA/EMA), clinical trial results with phase noted. Not needed: unverified "folk" remedies, supplement ads.
Description
Treatment innovation is increasingly focused on shifting effective therapies from injectable to oral form and on treating weight loss and glycemic control as joint goals, while biosimilars steadily widen access to lower-cost options.
New FDA Approvals
Awiqli (insulin icodec), approved March 26, 2026, is a once-weekly basal insulin shown in the ONWARDS phase 3a program (roughly 2,680 adults with uncontrolled type 2 diabetes across four trials) to reduce A1C comparably to daily basal insulin. Langlara (insulin glargine-aldy), approved April 29, 2026, is a long-acting biosimilar interchangeable with Lantus.
Oral GLP-1 Progress
Lilly's oral GLP-1 candidate, orforglipron, showed superior glycemic control in two successful Phase 3 trials, reducing A1C by 1.3–1.6 percentage points and producing roughly 8% body weight loss — reinforcing its potential as a future foundational oral treatment.
New Oral Formulation
Lynavoy, a new higher-dose oral semaglutide formulation intended to eventually replace Rybelsus, showed roughly 15–17% body weight reduction among trial completers.